STOCK TITAN

ASTELLAS PHARMA UNSP/ADR - ALPMY STOCK NEWS

Welcome to our dedicated page for ASTELLAS PHARMA UNSP/ADR news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on ASTELLAS PHARMA UNSP/ADR stock.

Astellas Pharma Inc. is a global pharmaceutical company with operations in over 70 countries. The company focuses on creating innovative drugs to treat diseases with high unmet medical needs by emphasizing Biology and Modality. Beyond traditional pharmaceuticals, Astellas is exploring Rx+® healthcare solutions in collaboration with cutting-edge technology partners. Astellas recently opened a state-of-the-art West Coast Innovation Center in South San Francisco, enhancing its commitment to biotech innovation.

The company is actively involved in research and development, with recent advancements in cancer therapies like zolbetuximab, a monoclonal antibody targeting gastric and gastroesophageal cancers. Astellas' collaborations with Pfizer and Merck, as well as YASKAWA Electric Corporation, demonstrate its commitment to pioneering research and creating new treatment paradigms by integrating pharmaceutical and robotics technologies.

Rhea-AI Summary
Takeda, Astellas, and Sumitomo Mitsui Banking have announced a master agreement to establish a joint venture company dedicated to the incubation of early drug discovery programs in Japan. The new company aims to advance innovative drug discovery programs, foster entrepreneurship, and create start-up companies to unleash the potential of the drug discovery ecosystem in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
Rhea-AI Summary
Astellas Pharma Inc. announces the acceptance of the sBLA for enfortumab vedotin with KEYTRUDA as a combination therapy for first-line treatment of urothelial cancer in China, potentially offering an alternative to platinum-containing chemotherapy. The pivotal trial results show significant improvements in overall and progression-free survival, potentially changing the treatment paradigm for this life-threatening condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Summary
Iveric Bio, An Astellas Company, receives a permanent J-code (J2782) effective April 1, 2024, for IZERVAY™, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The J-code will streamline billing and reimbursement processes, increasing patient access to the FDA-approved treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
Rhea-AI Summary
Astellas Pharma Inc. announces MHLW approval of VYLOY for gastric cancer treatment, making it the first CLDN18.2-targeted therapy globally. Approval based on successful Phase 3 trials showing significant improvement in progression-free and overall survival rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
-
Rhea-AI Summary
Astellas Pharma Inc. announced a positive CHMP opinion recommending approval of XTANDI for the treatment of high-risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patients in the EU. This decision could make XTANDI the first NHT treatment available for this patient population in the EU by June 2024. The positive opinion is based on Phase 3 EMBARK trial results, indicating potential approval for XTANDI in the EU and other regions beyond the US, where it was already approved for a similar indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
-
Rhea-AI Summary
Astellas Pharma US, Inc. receives FDA approval for CRESEMBA to treat serious fungal infections in children, granting seven years of market exclusivity. The drug is the first to be approved for pediatric patients as young as one, providing a vital treatment option for rare and life-threatening infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
Rhea-AI Summary
Astellas Pharma Inc. announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, a nonhormonal compound for treating vasomotor symptoms in Japanese women. The company aims to provide a novel treatment option for menopausal symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
-
Rhea-AI Summary
Astellas Pharma Inc. receives priority review for PADCEV™ and KEYTRUDA® combination therapy for urothelial cancer treatment, based on positive Phase 3 trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
-
Rhea-AI Summary
Astellas Pharma Inc. and Kelonia Therapeutics announce a research collaboration to develop novel Immuno-Oncology therapeutics using Xyphos Biosciences' ACCEL™ technology and Kelonia's iGPS® platform. The agreement includes upfront payments of US $40 million for the first program, potential milestones and contingency payments of up to US $800 million, and tiered royalties on net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
Rhea-AI Summary
Astellas Pharma Inc. announces the addition of a Chief Digital & Transformation Officer to its top management effective April 1, 2024. Nick Eshkenazi will be appointed to the position, bringing experience in driving complex business transformation and digital technology in various industries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none

FAQ

What is the current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY) is $11.71 as of October 11, 2024.

What is the market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY) is approximately 22.5B.

What is Astellas Pharma Inc. known for?

Astellas Pharma Inc. is recognized as a leading global pharmaceutical company operating in over 70 countries, focusing on developing innovative drugs for diseases with high unmet medical needs.

What recent achievements has Astellas Pharma Inc. made?

Astellas recently inaugurated a modern West Coast Innovation Center in South San Francisco, enhancing its presence in the biotech ecosystem.

What is zolbetuximab, and why is it significant?

Zolbetuximab is an investigational monoclonal antibody aimed at treating gastric and gastroesophageal cancers and is a testament to Astellas' commitment to pioneering cancer therapies.

How does Astellas collaborate with other companies like Pfizer, Merck, and YASKAWA Electric Corporation?

Astellas collaborates with Pfizer, Merck, and YASKAWA Electric Corporation to advance research and development in innovative treatments through partnerships that integrate pharmaceutical and robotics technologies.

What is Astellas Pharma Inc.'s focus beyond traditional pharmaceuticals?

Astellas is exploring Rx+® healthcare solutions with cutting-edge technology partners, aiming to create innovative treatment approaches beyond traditional pharmaceuticals.

ASTELLAS PHARMA UNSP/ADR

OTC:ALPMY

ALPMY Rankings

ALPMY Stock Data

22.52B
1.73B
0.02%
Drug Manufacturers - General
Healthcare
Link
United States of America
Tokyo